Cell-free DNA Quantification for Predictive Marker of Palliative Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is design to address, as follows:

1. correlation between fluorescence-based CFD measurements and tumor burden (primary tumor size, number of metastatic sites)
2. fluorescence-based CFD measurements and changes are related to tumor response. Based on the results of this study, the role of fluorescence-based CFD as a predictive biomarker for palliative chemotherapy is to be confirmed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer

NCT03512847

Metastatic Nonsmall Cell Lung Cancer

COMPLETED

Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study

NCT06105177

Lung Cancer

RECRUITING

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

NCT07012759

Biomarkers Lung Adenocarcinoma Pleural Effusion

NOT_YET_RECRUITING

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

NCT06227728

Non Small Cell Lung Cancer Breast Cancer Colorectal Cancer +4 more

RECRUITING

Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients

NCT05066945

Small Cell Lung Cancer Extensive Stage

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* It is important to check the response to chemotherapy. Currently, it is mostly evaluated as a radiologic response or, rarely the change of tumor markers.
* In the case of radiologic response tests at intervals of 6-8 weeks, there are cases where the economic burden and radiation exposure risk, additionally evaluation lesion is lack in a few case. Except for prostate cancer and ovarian cancer, the majority of carcinomas do not have cancer markers for assessing treatment response. Therefore, there is a need for biomarkers that can predict the response of anticancer treatment.
* In many studies, it has been reported that various types of circulating cell free DNA (CFD) are increased in various cancer types.
* Recently, a fluorescence based CFD method that can directly measure nucleic acids without a DNA extraction process has been developed, which makes testing simpler and more economical, and can be conveniently applied to cancer diagnosis and treatment response.
* This study is plan to evaluate the relationship between fluorescence-based CFD and treatment response in patients starting palliative chemotherapy, and check whether it can serve as a response evaluation for palliative chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cell-Free Nucleic Acids Biomarkers Fluorescence Palliative Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically or cytologically confirmed initially metastatic or recurrent cancer who are expected to undergo primary palliative chemotherapy (patients who relapse after adjuvant chemotherapy before/after existing surgery can also be enrolled regardless of period)
* Patients with definitive tumor burden (Patients who do not have residual lesions due to metastasectomy are excluded. However, measurable lesions according to RECIST 1.1 are not mandatory, and evaluable lesions are possible)
* ECOG PS 0-2
* Adequate bone marrow, renal function, liver function to receive chemotherapy
* Patients with informed consent form

Exclusion Criteria

* Patients with treating antibiotic treatment within 3 days of study enrollment due to overt or suspected infection
* Other serious illness or medical condition

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No